



The 26th JFCR-ISCC New Antitumor Agents under Development in the US, Europe and Japan

2022 December 7 (Wed) 12:50 -18:00
December 8 (Thu) 9:00 -15:20

Miraikan

National Museum of Emerging Science and Innovation
2-3-6, Aomi, Koto-ku, Tokyo, Japan

Dec. 7 (Wed)

13:00 - **Poster Flash Talks**
13:50 - **Poster Viewing**

Session 1 **New emerging molecular targets and drugs**

14:40 -

Koji Ichikawa *Taiho*

TAS0612, a potent RSK/AKT/S6K inhibitor targeting cancers with PI3K and MAPK pathway aberrations

Victor Moreno *START*

Current advances in adoptive cell therapy for solid tumors

Session 2 **Targeting KRAS/SOS**

16:05 -

Supported by MEXT Grant-in-Aid for Scientific Research on Innovative Areas "Integrated Analysis and Regulation of Cellular Diversity (4904)"



Ryan Corcoran *MGH*

Overcoming resistance to KRAS inhibition

Yoshihisa Kobayashi *NCC*

Silent mutations associated with oncogenic function of RAS

Norbert Kraut *Boehringer Ingelheim*

Targeting KRAS for cancer care

Dec. 8 (Thu)

Meet-the-Expert Session

9:00 -

Rethinking early phase clinical trials in oncology: Dose optimization

Lillian Siu *Princess Margaret Cancer Centre*

Session 3 **Targeted protein degradation and PROTACs**

10:00 -

Hiroshi Handa *Tokyo Medical Univ.*

Identification of thalidomide target CRBN to the development of targeted protein degraders

Alessio Ciulli *Univ. Dundee*

How PROTAC degraders work: Design principles and drug development for challenging cancer targets

Debbie Chirnomas *Arvinas*

TBD

Luncheon Seminar

12:30 -

The oncogene-dependent resistance to reprogramming unveils cancer therapeutic targets

Yasuhiro Yamada *Univ. Tokyo*

Session 4 **Next generation antibody drug therapy**

13:40 -

Soichiro Nishijima *Daiichi Sankyo*

Clinical development of DXd-ADC franchise

Yohei Otake *Eisai*

Discovery and early clinical development of folate receptor a targeting ADC, farletuzumab ecteribulin

Yosuke Togashi *Okayama Univ*

TIGIT blockade therapies: Can they overcome resistance to PD-1 blockade therapies?

Contact : Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
jfc-r-iscc@ml.jfcr.or.jp

<http://iscc.umin.jp/>

The 26th JFCR-ISCC is supported by following companies: MSD K.K., Kyowa Kirin Co., Ltd., Astellas Pharma Inc., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Ono Pharmaceutical Co., Ltd., Sanofi K.K., Takeda Pharmaceutical Co., Ltd., Yakult Honsha Co., Ltd., Taiho Pharmaceutical Co., Ltd.